Renal Cancer - Results from #2400

Optimized Combination of HDACI and TKI Efficiently Inhibits Metabolic Activity in Renal Cell Carcinoma and Overcomes Sunitinib Resistance. November 3, 2020

BRDT is a novel regulator of eIF4EBP1 in renal cell carcinoma. November 2, 2020

The impact of intraoperative bleeding on the risk of chronic kidney disease after nephron-sparing surgery. November 2, 2020

Endocytosis-mediated replenishment of amino acids favors cancer cell proliferation and survival in chromophobe renal cell carcinoma. November 2, 2020

circ_001504 promotes the development of renal cell carcinoma by sponging microRNA-149 to increase NUCB2. October 30, 2020

Long non-coding RNAs and renal cell carcinoma. October 30, 2020

Genetic Analysis Identifies the Role of HLF in Renal Cell Carcinoma. October 30, 2020

Efficacy and Safety of Axitinib Therapy After Nivolumab for Patients With Metastatic Renal Cell Cancer. October 29, 2020

The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium. October 29, 2020

Stereotactic radiotherapy combined with immune- or targeted therapy for metastatic renal cell carcinoma. October 29, 2020

Prognostic Value of YTHDF2 in Clear Cell Renal Cell Carcinoma. October 28, 2020

Organotypic primary blood vessel models of clear cell renal cell carcinoma for single-patient clinical trials. October 28, 2020

Differentiation of renal cell tumors with morphological cocktails using a minimal panel of immunohistochemical markers. October 28, 2020

Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE). October 28, 2020

Suppressive effects of RASAL2 on renal cell carcinoma via SOX2/ERK/p38 MAPK pathway. October 27, 2020

Prognostic value of plasminogen activator inhibitor-1 in biomarker exploration using multiplex immunoassay in patients with metastatic renal cell carcinoma treated with axitinib. October 27, 2020

A risk stratification model based on four novel biomarkers predicts prognosis for patients with renal cell carcinoma. October 27, 2020

Absorption of the orally active multikinase inhibitor axitinib as a therapeutic index to guide dose titration in metastatic renal cell carcinoma. October 26, 2020

Transplant Radical Nephrectomy and Transplant Radical Nephroureterectomy for Renal Cancer: Postoperative and Survival Outcomes. October 26, 2020

Dynamic 68Ga-PSMA-11 PET/CT for the primary evaluation of localized renal mass: a prospective study. October 26, 2020

Page 121 of 456